Compare Stocks: TSHA, HHH, CGON, and MIRM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$74.62 -1.3%	$74.06	$35.64 ▼ $80.97	$6.70B	0.24	665,333 shs	1.78 million shs
HHH Howard Hughes	$60.20 -2.2%	$65.83	$60.09 ▼ $91.07	$3.68B	1.14	529,399 shs	1.35 million shs
MIRM Mirum Pharmaceuticals	$91.83 -7.1%	$103.81	$63.23 ▼ $130.00	$6.42B	0.49	532,173 shs	1.80 million shs
TSHA Taysha Gene Therapies	$5.02 -2.7%	$5.79	$2.71 ▼ $7.30	$1.68B	1.19	2.55 million shs	9.12 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	-1.32%	+3.14%	-7.51%	+22.17%	+97.83%
HHH Howard Hughes	-2.26%	-2.26%	-11.67%	-10.07%	-26.80%
MIRM Mirum Pharmaceuticals	-7.07%	-6.51%	-10.18%	-14.28%	+25.55%
TSHA Taysha Gene Therapies	-2.71%	0.00%	-21.93%	-21.81%	+73.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$74.62 -1.3%	$74.06	$35.64 ▼ $80.97	$6.70B	0.24	665,333 shs	1.78 million shs
HHH Howard Hughes	$60.20 -2.2%	$65.83	$60.09 ▼ $91.07	$3.68B	1.14	529,399 shs	1.35 million shs
MIRM Mirum Pharmaceuticals	$91.83 -7.1%	$103.81	$63.23 ▼ $130.00	$6.42B	0.49	532,173 shs	1.80 million shs
TSHA Taysha Gene Therapies	$5.02 -2.7%	$5.79	$2.71 ▼ $7.30	$1.68B	1.19	2.55 million shs	9.12 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	-1.32%	+3.14%	-7.51%	+22.17%	+97.83%
HHH Howard Hughes	-2.26%	-2.26%	-11.67%	-10.07%	-26.80%
MIRM Mirum Pharmaceuticals	-7.07%	-6.51%	-10.18%	-14.28%	+25.55%
TSHA Taysha Gene Therapies	-2.71%	0.00%	-21.93%	-21.81%	+73.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.73	Moderate Buy	$87.78	17.63% Upside
HHH Howard Hughes	2.00	Hold	$79.00	31.22% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$137.31	49.53% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	154.37% Upside

Current Analyst Ratings Breakdown

Latest TSHA, HHH, CGON, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	TSHA Taysha Gene Therapies	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/14/2026	HHH Howard Hughes	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/27/2026	MIRM Mirum Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$137.00
8/27/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/27/2026	MIRM Mirum Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$137.00
8/7/2026	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$81.00 ➝ $79.00
8/7/2026	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $85.00
8/7/2026	CGON CG Oncology	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$82.00 ➝ $85.00
8/6/2026	HHH Howard Hughes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)
8/6/2026	MIRM Mirum Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
8/6/2026	MIRM Mirum Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$123.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,637.21	N/A	N/A	$9.33 per share	8.00
HHH Howard Hughes	$1.47B	2.44	$6.09 per share	9.88	$64.69 per share	0.93
MIRM Mirum Pharmaceuticals	$521.31M	11.44	$0.05 per share	1,938.44	$6.12 per share	15.00
TSHA Taysha Gene Therapies	$9.77M	167.42	N/A	N/A	$0.90 per share	5.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
HHH Howard Hughes	$123.90M	$4.94	12.19	19.48	N/A	12.31%	7.51%	2.41%	N/A
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
TSHA Taysha Gene Therapies	-$109M	-$0.42	N/A	N/A	N/A	N/A	-56.19%	-41.84%	11/3/2026 (Estimated)

Latest TSHA, HHH, CGON, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/5/2026	Q2 2026	HHH Howard Hughes	$0.49	$2.68	+$2.19	$2.68	N/A	$1.12 billion
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
HHH Howard Hughes	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
HHH Howard Hughes	1.35	2.31	2.31
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
TSHA Taysha Gene Therapies	0.13	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
HHH Howard Hughes	93.83%
MIRM Mirum Pharmaceuticals	N/A
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
HHH Howard Hughes	47.70%
MIRM Mirum Pharmaceuticals	8.32%
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
HHH Howard Hughes	500	59.72 million	31.23 million	Optionable
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable
TSHA Taysha Gene Therapies	99	325.83 million	314.50 million	Optionable

TSHA, HHH, CGON, and MIRM Headlines

Recent News About These Companies

Wolfe Research Initiates Coverage on Taysha Gene Therapies (NASDAQ:TSHA)

September 19 at 1:54 AM | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Earns Outperform Rating from Analysts at Wolfe Research

September 17 at 9:05 AM | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Analysts

September 17 at 3:46 AM | americanbankingnews.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Analysts

September 12, 2026 | marketbeat.com

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

September 11, 2026 | seekingalpha.com

These 3 Risky Stocks Could Be Sitting on 100% Upside (TSHA)

...

September 7, 2026 | marketbeat.com

Wellington Management Group LLP Acquires 3,349,244 Shares of Taysha Gene Therapies, Inc. $TSHA

September 6, 2026 | marketbeat.com

Bank of New York Mellon Corp Purchases New Position in Taysha Gene Therapies, Inc. $TSHA

September 6, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $9.94 Million Holdings in Taysha Gene Therapies, Inc. $TSHA

September 5, 2026 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

Bank of America Corp DE Has $7.50 Million Stake in Taysha Gene Therapies, Inc. $TSHA

August 26, 2026 | marketbeat.com

Taysha Gene Therapies Earnings Call Highlights Pivotal Progress

August 23, 2026 | tipranks.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down - Should You Sell?

August 20, 2026 | marketbeat.com

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

August 18, 2026 | finance.yahoo.com

Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)

August 14, 2026 | theglobeandmail.com

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

August 13, 2026 | finance.yahoo.com

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | finanznachrichten.de

Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...

August 12, 2026 | finance.yahoo.com

Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026

August 12, 2026 | seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TSHA, HHH, CGON, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

$74.62 -1.00 (-1.32%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$72.49 -2.13 (-2.85%)

As of 09/18/2026 07:30 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Howard Hughes NYSE:HHH

$60.20 -1.34 (-2.17%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$60.40 +0.20 (+0.33%)

As of 09/18/2026 07:56 PM Eastern

Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.

Mirum Pharmaceuticals NASDAQ:MIRM

$91.83 -6.99 (-7.07%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$92.88 +1.05 (+1.14%)

As of 09/18/2026 07:30 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Taysha Gene Therapies NASDAQ:TSHA

$5.02 -0.14 (-2.71%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.02 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TSHA, HHH, CGON, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TSHA, HHH, CGON, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TSHA, HHH, CGON, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TSHA, HHH, CGON, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

Howard Hughes NYSE:HHH

Mirum Pharmaceuticals NASDAQ:MIRM

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TSHA, HHH, CGON, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TSHA, HHH, CGON, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TSHA, HHH, CGON, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TSHA, HHH, CGON, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

Howard Hughes NYSE:HHH

Mirum Pharmaceuticals NASDAQ:MIRM

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools